カテゴリ： GlobalData, アメリカ, 企業調査

Vertex Pharmaceuticals Inc (VRTX)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Vertex Pharmaceuticals Inc (VRTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9934
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：83
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Vertex Pharmaceuticals Inc (Vertex) is a biotechnology company that carries out the discovery, development and commercialization of transformative drugs for the treatment of serious and life-threatening diseases. The company product portfolio includes Orkambi (ivacaftor/lumacaftor) and Kalydeco (ivacaftor) for the treatment of cystic fibrosis (CF). Through its research and development (R&D) efforts, the company focuses on influenza, cancer, neurological diseases and disorders including pain and cystic fibrosis. Vertex has R&D centers and commercial offices in North America, South America, Europe and Australia. The company offers its products in the US, Europe, Australia and Canada. Vertex is headquartered in Boston, Massachusetts, the US.

Vertex Pharmaceuticals Inc (VRTX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Vertex Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Vertex Pharma Acquires CTP-656 from Concert Pharma 13
Vertex Pharma Acquires Cystic Fibrosis Assets from AmorChem 15
Partnerships 16
Vertex Pharma Enters into Partnership Agreement with Genomics 16
Q-State Biosciences Enters into Agreement with Vertex Pharmaceuticals 17
X-Chem Enters into Agreement with Vertex Pharma 18
Vertex Pharma Enters into Research Collaboration with CRISPR Therapeutics 19
Vertex Pharma Enters into Co-Development Agreement with Parion Sciences 20
Licensing Agreements 21
Vertex Pharma Enters into Licensing Agreement with CRISPR Therapeutics 21
Merck Enters into Licensing Agreement with Vertex Pharma 22
Vertex Pharma Enters into Licensing Agreement with Moderna Therapeutics 23
Enterome Bioscience Enters into Licensing Agreement with Vertex Pharma 24
EIP Pharma Enters into Licensing Agreement with Vertex Pharma 25
Vertex Pharma Enters into Licensing Agreement with BioAxone Biosciences for VX-210 26
Vertex Pharma Enters into Licensing Agreement with Janssen Pharma for VX-787 27
Asset Transactions 28
Trek Therapeutics Acquires Rights to Two Antiviral Inhibitors from Vertex Pharma 28
Spero Therapeutics Acquires Rights to Novel Gyrase Inhibitors from Vertex Pharma 29
Janssen Pharma Acquires Royalty Rights To Incivo From Vertex Pharma For US$152 Million 30
Vertex Pharmaceuticals Inc – Key Competitors 31
Vertex Pharmaceuticals Inc – Key Employees 32
Vertex Pharmaceuticals Inc – Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Recent Developments 36
Financial Announcements 36
Oct 24, 2018: Vertex reports third-quarter 2018 financial results 36
Jul 25, 2018: Vertex reports second-quarter 2018 financial results 37
Apr 26, 2018: Vertex Reports First-Quarter 2018 Financial Results 39
Jan 31, 2018: Vertex Reports Full-Year and Fourth-Quarter 2017 Financial Results 41
Oct 25, 2017: Vertex Reports Third-Quarter 2017 Financial Results 44
Jul 26, 2017: Vertex Reports Second-Quarter 2017 Financial Results 47
Apr 27, 2017: Vertex Reports First-Quarter 2017 Financial Results 50
Jan 25, 2017: Vertex Reports Full-Year and Fourth-Quarter 2016 Financial Results 53
Corporate Communications 55
Aug 23, 2018: Vertex names Ludovic Fenaux as senior vice president, international commercial operations 55
Jun 14, 2018: The Vertex Foundation and Employees Donate $1 Million Through Matching Gift Program 56
Mar 29, 2018: Vertex Pharmaceuticals Names Kimberly A. White As Senior Vice President And Chief Communications Officer 57
Feb 26, 2018: Vertex Names Reshma Kewalramani As Chief Medical Officer 58
Oct 17, 2017: Vertex Announces 10-Year, $500 Million Corporate Giving Commitment 59
Sep 06, 2017: Vertex Appoints Tom Graney as Senior Vice President and Chief Financial Officer 60
Jun 08, 2017: Vertex Names Dr. Alan Garber, Provost of Harvard University, to its Board of Directors 61
Government and Public Interest 62
Oct 04, 2018: Vertex’s cystic fibrosis drugs become publicly available in Denmark 62
Nov 01, 2017: Vertex Announces New $750,000 Program to Support the Work of the Next Generation of Cystic Fibrosis Researchers 63
May 04, 2017: Vertex Grants $1 Million to 15 Non-profit Organizations to Advance Initiatives for People Living with Cystic Fibrosis 64
Product News 65
07/18/2017: Vertex Provides Update on VX-445 development program 65
05/08/2018: Evaluating the Impact of Precision Medicine: How Ivacaftor Reduces Hospitalizations of Patients with Cystic Fibrosis 66
Product Approvals 67
Jan 20, 2017: Concert Pharmaceuticals Receives FDA Orphan Drug Designation for CTP-656 for the Treatment of Cystic Fibrosis 67
Clinical Trials 68
Apr 26, 2018: Vertex Initiates Phase 3 Studies of VX-445, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis 68
Feb 21, 2018: Vertex Initiates First Phase 3 Study of VX-659, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis 70
Feb 01, 2018: Vertex Selects Next-Generation Corrector, VX-445, to Advance into Phase 3 Development as Part of Two Different Triple Combination Regimens for People with Cystic Fibrosis 71
Feb 01, 2018: Vertex Selects Next-Generation Corrector, VX-659, to Advance into Phase 3 Development as Part of Two Different Triple Combination Regimens for People with Cystic Fibrosis 73
Jul 18, 2017: Vertex Announces Positive Phase 2 Data from Triple Combination Regimen with VX-440 75
Jul 18, 2017: Vertex Announces Positive Phase I Data from Triple Combination Regimen with VX-659 77
Jan 17, 2017: Concert Pharmaceuticals Provides Further Details on CTP-656 Development in U.S. and Europe 79
Other Significant Developments 80
Jan 08, 2017: Vertex Provides Update on Business and Financial Performance and Research and Development Programs 80
Appendix 83
Methodology 83
About GlobalData 83
Contact Us 83
Disclaimer 83

List of Tables
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Vertex Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Vertex Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Vertex Pharma Acquires CTP-656 from Concert Pharma 13
Vertex Pharma Acquires Cystic Fibrosis Assets from AmorChem 15
Vertex Pharma Enters into Partnership Agreement with Genomics 16
Q-State Biosciences Enters into Agreement with Vertex Pharmaceuticals 17
X-Chem Enters into Agreement with Vertex Pharma 18
Vertex Pharma Enters into Research Collaboration with CRISPR Therapeutics 19
Vertex Pharma Enters into Co-Development Agreement with Parion Sciences 20
Vertex Pharma Enters into Licensing Agreement with CRISPR Therapeutics 21
Merck Enters into Licensing Agreement with Vertex Pharma 22
Vertex Pharma Enters into Licensing Agreement with Moderna Therapeutics 23
Enterome Bioscience Enters into Licensing Agreement with Vertex Pharma 24
EIP Pharma Enters into Licensing Agreement with Vertex Pharma 25
Vertex Pharma Enters into Licensing Agreement with BioAxone Biosciences for VX-210 26
Vertex Pharma Enters into Licensing Agreement with Janssen Pharma for VX-787 27
Trek Therapeutics Acquires Rights to Two Antiviral Inhibitors from Vertex Pharma 28
Spero Therapeutics Acquires Rights to Novel Gyrase Inhibitors from Vertex Pharma 29
Janssen Pharma Acquires Royalty Rights To Incivo From Vertex Pharma For US$152 Million 30
Vertex Pharmaceuticals Inc, Key Competitors 31
Vertex Pharmaceuticals Inc, Key Employees 32
Vertex Pharmaceuticals Inc, Subsidiaries 34

List of Figures
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Vertex Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Vertex Pharmaceuticals Inc (VRTX)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Hung Hing Printing Group Limited：企業の戦略・SWOT・財務情報
    Hung Hing Printing Group Limited - Strategy, SWOT and Corporate Finance Report Summary Hung Hing Printing Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Victek Co., Ltd.：企業の戦略・SWOT・財務情報
    Victek Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Victek Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Alibaba Group Holding Limited：企業の戦略・SWOT・財務情報
    Alibaba Group Holding Limited - Strategy, SWOT and Corporate Finance Report Summary Alibaba Group Holding Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Orlando Utilities Commission：電力：M&Aディール及び事業提携情報
    Summary Orlando Utilities Commission (OUC) is a municipally-owned public utility that provides water and electric services. The commission generates, transmits, and distributes electricity and water to residential and commercial customers. It also constructs, operates and maintains electric and wate …
  • China Communications Construction Co Ltd：戦略・SWOT・企業財務分析
    China Communications Construction Co Ltd - Strategy, SWOT and Corporate Finance Report Summary China Communications Construction Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Sibur Holding：石油・ガス：M&Aディール及び事業提携情報
    Summary Sibur Holding (Sibur) is a vertically integrated gas processing and petrochemicals company. Sibur is one of the major players in Russian petrochemical industry delivering large volumes of associated petroleum gas. The company offers liquefied petroleum gas, natural gas, naphtha and natural g …
  • Indeck Energy Services Inc：企業の戦略的SWOT分析
    Indeck Energy Services Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Verde Science Inc (VRCI)：企業の財務・戦略的SWOT分析
    Summary Verde Science Inc (Verde Science), formerly Rango Energy Inc is a pharmaceutical research and development company that explores phytochemicals and drugs to create novel formulations. The company offers research and development services in bioprocess technology, molecular virology and immunol …
  • Beckman Coulter, Inc.：企業の戦略・SWOT・財務情報
    Beckman Coulter, Inc. - Strategy, SWOT and Corporate Finance Report Summary Beckman Coulter, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Seoul City Gas Co Ltd (017390)：企業の財務・戦略的SWOT分析
    Seoul City Gas Co Ltd (017390) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Bone Solutions Inc-医療機器分野：企業M&A・提携分析
    Summary Bone Solutions Inc (BSI) is a medical device company that offers orthobiologics technology solutions. The company also develops magnesium oxide based technologies for multitude of orthopedic applications. It offers osteocrete bone graft substitute that provides adhere ligaments and tendons t …
  • Idorsia Pharmaceutical Ltd (IDIA)：製薬・医療：M&Aディール及び事業提携情報
    Summary Idorsia Pharmaceutical Ltd (Idorsia) is a manufacturer and developer of medicine that discovers, develops various therapies. The company provides pipeline portfolio such as investigational candidates targeted at the treatment of resistant hypertension, chronic insomnia, vasospasm, and system …
  • Myriad Genetics Inc (MYGN)：企業の財務・戦略的SWOT分析
    Myriad Genetics Inc (MYGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Reckitt Benckiser Group Plc (RB.)：製薬・医療：M&Aディール及び事業提携情報
    Summary Reckitt Benckiser Group Plc (RB) is a consumer health and hygiene company that manufactures and markets household, toiletry and health care products. These consist of air fresheners, laundry products, dishwashing detergents, disinfectant sprays, water softeners, household cleaners, and perso …
  • AXA Life Insurance Co., Ltd.：企業の戦略・SWOT・財務情報
    AXA Life Insurance Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary AXA Life Insurance Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • South Jersey Industries Inc (SJI)：石油・ガス：M&Aディール及び事業提携情報
    Summary South Jersey Industries Inc (SJI) is an energy services holding company that sources and supplies natural gas and electricity. It develops, owns, and operates on-site energy production facilities. The company provides wholesale commodity marketing and fuel management services; and also offer …
  • Enel Generacion Peru SAA (EDEGELC1)：企業の財務・戦略的SWOT分析
    Summary Enel Generacion Peru SAA (Enel Generacion) a subsidiary of Enel Americas SA, is a power generation company. It offers transmission and distribution of electricity. The company generates electricity through thermal and hydroelectric sources. It also carries out hydroelectric plant generation …
  • Biafo Industries Ltd (BIFO)：企業の財務・戦略的SWOT分析
    Biafo Industries Ltd (BIFO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Vascular Biogenics Ltd (VBLT)：製薬・医療：M&Aディール及び事業提携情報
    Summary Vascular Biogenics Ltd (VBL) is a clinical biopharmaceutical company that discovers, develops and commercializes treatments for cancer. The company’s product pipeline includes VB-111. VBL’s product VB-111 is an anti-angiogenic agent for the specific inhibition of tumor vascular growth for ca …
  • Agilent Technologies, Inc.：企業の戦略・SWOT・財務情報
    Agilent Technologies, Inc. - Strategy, SWOT and Corporate Finance Report Summary Agilent Technologies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆